A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS
Status:
Withdrawn
Trial end date:
2016-04-04
Target enrollment:
Participant gender:
Summary
The purpose of the study is to treat patients with Ductal carcinoma in situ (DCIS) with a
combined treatment of DC1 vaccine with Trastuzumab. In this study the investigators will
assess the safety and immunogenicity of the combination therapy. The target population is
women over 18 years of age and have a diagnosis of DCIS that express HER-2 3 positive.
Participants will receive 6 vaccines along with 2 doses of trastuzumab.
This study began at the Abramson Cancer Center of the University of Pennsylvania and will
continue at H. Lee Moffitt Cancer Center and Research Institute.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute